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ABSTRACT
Objective: Compare annual health-care costs and resource utilization
associated with olanzapine versus quetiapine for treating schizophrenia in
a Medicaid population.
Methods: Adult schizophrenia patients were selected from deidentiﬁed
Pennsylvania Medicaid claims database (1999–2003). Included patients
were continuously enrolled and initiated with olanzapine or quetiapine
monotherapy after a 90-day washout period. Treatment costs were calcu-
lated for 1-year post-therapy initiation and inﬂation adjusted to year 2003.
To control for selection bias, olanzapine and quetiapine patients were 1:1
matched using an optimal matching algorithm on propensity score, which
was generated using logistic regression controlling for demographics, prior
drug therapy, utilization, and costs. Treatment costs for the matched
cohorts were compared directly, as well as using a difference-in-difference
analysis.
Results: A total of 6929 patients treated with olanzapine and 2321 with
quetiapine met inclusion criteria. Quetiapine patients appeared more
severe at baseline. After propensity score matching, 2321 patient pairs
had similar baseline characteristics, including total costs. Compared with
matched quetiapine patients, for the 1-year postindex period, olanzapine
patients had similar drug costs ($6131 vs. $6014, P = 0.326), lower
medical costs ($9897 vs. $11,218, P = 0.0128), and lower total
health-care costs ($16,028 vs. $17,232, P = 0.0279). Lower psychiatric
hospitalization costs account for most of the total cost difference.
Difference-in-difference regression analysis conﬁrmed olanzapine’s eco-
nomic advantage. Further adjusting for baseline variations, the total cost
advantage of olanzapine patients was $962 (P = 0.032), and was mostly
because of reduced psychiatric hospitalization costs of $992 (P = 0.004).
Conclusion: Schizophrenia patients treated with olanzapine had lower
total costs than quetiapine patients, mostly attributable to reductions in
psychiatric hospitalization costs.
Keywords: antipsychotics, costs, olanzapine, optimal matching, propen-
sity score, quetiapine, resource utilization, schizophrenia.
Introduction
Schizophrenia is a costly condition with an economic burden
estimated at $62.7 billion in 2002 in the United States [1]. The
major goals of current pharmacotherapy for schizophrenia are to
achieve continuous relief from psychotic symptoms, to maximize
patient functioning and quality of life, and to maintain recovery
and prevent relapses. Atypical (or second generation) antipsy-
chotics are recommended as the preferred therapy for schizo-
phrenia by clinical guidelines in light of their better safety proﬁle
compared with typical (or ﬁrst generation) antipsychotics (e.g.,
lower incidence of extrapyramidal symptoms) [2]. In 2003,
atypical antipsychotics were prescribed to 71% of patients
treated with antipsychotics [3]; risperidone, olanzapine, and que-
tiapine were the most frequently prescribed atypical agents [3].
The Clinical Antipsychotic Trials in Intervention Effectiveness
(CATIE) study showed that olanzapine, compared with other
atypical antipsychotics, had longer time to all-cause discontinu-
ation [4,5]. Nevertheless, systematic reviews of randomized clini-
cal trials and more recent published trials of schizophrenia
patients did not show consistent beneﬁts for olanzapine com-
pared with other atypicals, especially quetiapine [6–13]. Overall,
the evaluation of the efﬁcacy and safety of atypicals are multidi-
mensional in terms of adherence, control of positive and negative
symptoms, extrapyramidal adverse events, and other safety
proﬁle, such as weight gain, and lipid proﬁles. Based on the
mixed ﬁndings regarding this wide array of clinical and safety
end points, there is no single atypical that is superior to others
across all endpoints.
Clinical trials do not commonly compare cost outcomes
among different atypicals. In contrast, observational studies in a
real-world setting have been conducted to assess the economic
consequences of the use of different antipsychotics. A number of
published observational studies compared the total treatment
costs between olanzapine and risperidone. Based on comprehen-
sive literature reviews of Liu et al. (2004) and Hargreaves and
Gibson (2005), there is no conclusive evidence to distinguish the
total costs associated with these two therapies [14,15]. Some
studies have analyzed the resource utilization associated with
different antipsychotic medications and yielded inconclusive
ﬁndings regarding olanzapine’s overall economic outcomes com-
pared with other atypical antipsychotics [16–18]. Nevertheless,
the economic comparison between olanzapine and quetiapine is
relatively rare. To the best of our knowledge, no published study
compared the total costs of care between olanzapine and que-
tiapine directly for schizophrenia patients in the United States.
Three articles presented relevant information on economic out-
comes with both olanzapine and quetiapine. Gianfrancesco et al.
(2006a, 2006b) compared the hospitalization rates across major
atypical antipsychotics and found no signiﬁcant differences
between olanzapine and quetiapine using two different claims
databases [19,20]. Both studies have relatively small sample
sizes. A recently published study using California Medicaid
database compared olanzapine, risperidone and quetiapine
versus conventional antipsychotics, and found that olanzapine
and risperidone, not quetiapine, were associated with
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reductions in total costs relative to typical antipsychotics [21].
Numerically, olanzapine had more favorable costs outcomes,
including psychiatric hospitalization cost reduction, which is not
consistent with ﬁndings from the Gianfrancesco et al. (2006a,
2006b) studies. In addition, a cost-effectiveness analysis based on
the CATIE study found that the total treatment costs were lower
with perphenazine than with atypical antipsychotics, and among
atypical antipsychotics, olanzapine appeared to be associated
with the lowest overall costs despite higher drug costs [22].
In light of the paucity in the literature with regard to obser-
vational studies comparing the economic outcomes of olanzapine
and quetiapine, the objective of this research is to compare the
annual health-care costs and resource utilization associated with
olanzapine versus quetiapine for treating schizophrenia in a
Medicaid population.
We used a Medicaid database for this research because we
consider the research question especially important to Medicaid.
State Medicaid programs are a major payer for all atypical antip-
sychotics prescriptions, which is a highly costly therapeutic class
and consumes a sizeable portion of the total pharmacy budget for
state Medicaid. Given the impact of this drug class on Medicaid
budget and differential safety and efﬁcacy proﬁles across different
atypical antipsychotics, it is essential for the policymakers to
comprehensively evaluate the economic outcomes associated
with different drugs, particularly the medical cost offset, such as
a reduction in hospitalizations. Combined with a sound method-
ology, conducting a comparison of economic outcomes using a
Medicaid database provides additional insights beyond clinical
trials, and is likely to provide useful information for policymak-
ers, as well as state government health management organiza-
tions, to make informed policy decisions.
Patients and Methods
Data
The data for this study consist of the Pennsylvania Medicaid
database (1999–2003), which includes deidentiﬁed information
on patients’ enrollment history, outpatient pharmacy claims,
behavioral health (BH) and general medical claims, including
diagnosis and procedures, physician visits, and hospitalizations.
This database includes approximately 2 million beneﬁciaries per
year. These data cover all Medicaid beneﬁciaries: low-income
families/children, people with disabilities, long-term care indi-
viduals, and supplemental coverage for low-income Medicare
beneﬁciaries. Data are available for both fee for service (FFS) and
managed care organization (MCO) sources of claims. We con-
ducted extensive data quality checks (e.g., to remove duplicate
claims) to insure that the data elements and observations are
complete and analytically meaningful.
Study Sample and Characteristics
All study sample patients were diagnosed with schizophrenia
(ICD-9-CM: 295.xx). To ensure speciﬁc selection of schizophre-
nia patients, we used the behavior health (BH) ﬁle only to iden-
tify those patients who had either an inpatient hospitalization
claim or two independent noninpatient medical claims with
schizophrenia diagnosis incurred on different dates. In addition,
patients were included if they had at least one qualiﬁed index
prescription that meets all the following criteria: 1) patients
received either olanzapine or quetiapine prescription (the index
prescription) during June 2000 to June 2002; 2) before the
index prescription of olanzapine or quetiapine, patients had a
washout period of at least 90 days, during which patients did
not receive either study medication, although prescriptions of
other antipsychotics were allowed; 3) the index prescription
was a monotherapy, though overlap with other antipsychotics
was allowed if the other drug was ﬁlled before this prescription
date; 4) a minimum of one monotherapy prescription of index
drug and the monotherapy period of 30 days or longer were
required. Included patients were 18 to 64 years of age as of the
index prescription date and were continuously enrolled for at
least 1 year before and 1 year after the index prescription date.
Because outpatient pharmacy claims are not complete for the
MCO source, patients who had MCO claims on or after the
index prescription date were excluded. We did not exclude
schizophrenia patients with bipolar diagnosis because we
wanted to include the entire schizophrenia population in the
analysis. Based on the ﬁrst atypical antipsychotic received (i.e.,
olanzapine or quetiapine), patients were classiﬁed as either an
olanzapine user or a quetiapine user regardless of their subse-
quent switching pattern. Therefore, this study analyzed the
treatment outcomes associated with the initial atypical psychot-
ics prescribed. Patients who were on both olanzapine and que-
tiapine at initiation were excluded.
Comorbidities were deﬁned using claims with International
Classiﬁcation of Diseases, 9th Revision, clinical Modiﬁcation
(ICD-9-CM) diagnosis codes, including 16 mental health comor-
bidities (deﬁned as the ﬁrst three digits of the ICD-9 diagnosis
codes from 290 to 316), and 8 major physical comorbidities,
which were selected using the ﬁrst three digits of ICD-9 codes
250 to 259, 270 to 279, 401 to 405, 410 to 414, and 428, and
which had greater than 1% prevalence in our study sample. In
addition, the number of mental comorbidities and the Deyo-
Charlson Comorbidities Index for each study patient were also
calculated [23].
Study Measures
The analysis compared resource utilization and costs between the
two treatment groups over the 12-month post-index period.
Medical resource utilization included the proportion of patients
with an emergency room visit and any inpatient hospitalization,
distinguishing between services that were psychiatric and non-
psychiatric related. Among medical resource users, the incidence
and number of inpatient admissions, inpatient days, and number
of emergency visits were also analyzed by psychiatric-related and
nonpsychiatric-related status. A medical claim is considered to be
psychiatric related if it appears in the BH ﬁle, indicates psychiatry
inpatient hospital as a place of service, or has a primary diagnosis
code for a mental health condition.
Pharmacy resource utilization included the use of any anti-
psychotics, antidepressants (including tricyclics, monamine
oxidase inhibitors (MAOIs) and second generation antidepres-
sants), mood stabilizers, benzodiazepines, hypnotics, anxiolytics,
antiparkinsonian medication, as well as the total number of days
with no antipsychotics usage. The medication possession ratio
(MPR) was calculated for patients who used antipsychotics. The
MPR was calculated as the ratio of the total number of nonover-
lapped days covered by antipsychotics during the year over 365.
The number of unique antipsychotic drugs used and the days of
simultaneous antipsychotic drugs use were also calculated.
Costs per patient were calculated as the amount reimbursed
from the payer’s perspective (i.e., Pennsylvania Medicaid) and
were inﬂated to year 2003 USD using the medical care compo-
nent of the Consumer Price Index. Medical service costs were
broken down by type of service (psychiatric or nonpsychiatric)
and by place of service (inpatient, ofﬁce/outpatient, emergency
department). Prescription drug costs were broken down by cost
of psychotropic drugs and cost of index drug (i.e., olanzapine
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and quetiapine). Total health-care costs were calculated as the
sum of medical service and drug costs.
Statistical Analysis Methods
Outcomes were ﬁrst compared descriptively across the
unmatched cohorts using Wilcoxon tests for continuous vari-
ables and chi-square tests for categorical variables. Although a
regression model approach is often used to control for differ-
ences among study samples, it assumes a given speciﬁcation
form for the model, which may bias the study ﬁndings. In
observational studies, selection bias can be a potential limita-
tion in evaluating the outcomes of alternative interventions,
because patients are not randomly assigned to different thera-
pies. Therefore, to control observable selection bias and render
two treatment cohorts more comparable at baseline, a propen-
sity score matching method was used. Propensity scores (i.e.,
the probability of receiving a given treatment conditional on
covariates) are used to reduce the dimensionality of covariates
into a single index. Assuming that there are no unmeasured
confounders, treatment effect can be estimated by conditioning
on the estimated propensity score [24]. Propensity scores can be
applied using four methods, which have been developed over
the past two decades in biostatistics and econometrics: match-
ing, stratiﬁcation (e.g., binning), inverse weighting, and covari-
ate adjustment [25].
Two major classes of matching algorithms are available for
propensity score: greedy matching and optimal matching.
Greedy matching ﬁnds the nearest neighbor without replace-
ment, and results were shown to be sensitive to the order of
matching [26]. Moreover, greedy matching often yields incom-
plete matches (i.e., certain patients in one group cannot ﬁnd a
match within an acceptable range in the other group), and, as
a result, both groups will have unmatched subjects after the
matching process. The incomplete matching limits the study
ﬁndings’ external validity because the ﬁndings and conclusions
could not be applied to the unmatched sample, which are often
very different in characteristics from the matched population.
In contrast, optimal matching involves minimizing the global
distance (or the average absolute propensity score distance)
between matched pairs, and hence the order of matching is
irrelevant, and at the same time, the balancing of differences in
baseline characteristics of matched pairs is also optimized. In
addition, because there is no clear cutoff threshold as in greedy
matching, it can retain the maximal number of matched pairs,
thereby minimizing the loss of sample size and improving
the external validity of study ﬁndings. Though the computer
algorithm can be complex, statistical routines are available
[27,28].
The following process was applied to implement the propen-
sity score method with optimal matching. First, patients’ baseline
characteristics were proﬁled during a 12-month preindex period.
These characteristics (including demographics, mental and physi-
cal comorbidities, resource utilization and costs) were compared
between the two study cohorts. Second, propensity scores (i.e.,
the probability of being in the quetiapine treatment group con-
ditional on observed baseline covariates) were generated using
logistic regressions and given patient baseline covariates, which
were selected using backward selection. Third, optimal matching
was applied to match olanzapine and quetiapine patients based
on propensity score using a SAS macro algorithm (SAS Institute,
Cary, NC) developed by the Mayo Clinic [27]. Finally, baseline
characteristics were compared for the full and the matched
cohorts over the 12-month preindex period. Once the propensity
score matching process was completed, outcomes were compared
using paired t tests for continuous variables, and McNemar’s
tests for categorical variables for matched pairs. Each cost com-
ponent was studied separately.
Sensitivity Analysis
Two sensitivity analyses were conducted to test the robustness of
the results. First, the monotherapy period was extended to
include patients who had at least two index drug prescriptions
and at least 60 days of monotherapy, and conducted similar
analyses as the ones described above. Because longer mono-
therapy indicates a better response and tolerability to the index
therapy, this sensitivity analysis allows investigating the extent to
which the economic difference between the two drugs remains
for patients who responded to initial therapy.
The second sensitivity analysis used a difference-in-difference
regression analysis, where the changes in 1-year treatment costs
were compared between the two cohorts. In combination with
propensity score matching, the difference-in-difference regression
analysis further controlled for baseline covariates to remove
unbalanced differences after matching, if any, between the two
treatment cohorts. Controlled baseline covariates include patient
demographics (age, sex, race), MCO, index year, comorbidities
and Charlson Comorbidity Index, prior medical resource utili-
zation, and prior medications use patterns. The combination of
propensity score method and covariate adjustment has been
shown to increase the validity of the estimate [29]. Paired t tests
were used to evaluate whether the difference-in-difference was
signiﬁcant.
Results
Baseline Characteristics
A total of 6929 olanzapine patients and 2321 quetiapine patients
met the sample selection criteria. Table 1 shows the patient selec-
tion criteria and corresponding sample sizes. As shown in the
Table 1 Sample selection
Sample selection criteria
Number of
unique patients
Patients with at least one inpatient claim with
schizophrenia diagnosis (295.xx) in the behavioral
health (BH) ﬁle, or at least two independent claims
with schizophrenia in BH
45,855
Patients who have at least one pharmacy claim for either
quetiapine (Q) or olanzapine (O)
29,265
Patients with a drug claim (Q or O) within the index
window (June 2000–June 2002)
22,167
Patients with at least one prescription of Q or O and 12
months of continuous eligibility before and after the
prescription
17,930
Patients who have no prescriptions of the potential index
drug for 90 days (washout period) before a potential
index drug prescription
14,733
Patients who were of age 18 to 64 as of the potential
index date
12,768
Patients with potential index dates on which Q and O
prescriptions were not ﬁlled on the same day
12,660
Patients who have at least one monotherapy
prescription(s) of the potential index drug and 30 days
of monotherapy period
10,442
Olanzapine Quetiapine
Patients with no managed care organization
claims on or after the index date, by
index drug
6,929 2,321
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baseline characteristics reported in Table 2 (column C), olanza-
pine patients were older (age 42.8 vs. 41.3, P < 0.0001), more
likely to be male (52.8% vs. 39.9%, P < 0.0001), and less likely
to be Caucasian than quetiapine patients. Olanzapine patients
also appeared less severe in general, as evidenced by fewer mental
health comorbidities (1.34 vs. 1.59, P < 0.0001), a lower Deyo-
Charlson Comorbidity Index (0.49 vs. 0.55, P < 0.0001), and a
lower likelihood to use any medical and pharmacy resources.
Study Outcomes
When generating propensity score using logistic regression with
backward selection, 19 variables were selected in the ﬁnal model.
The following variables increased the probability of receiving
quetiapine: being Caucasian, starting treatment in 2001, having
the following comorbidities (episodic mood disorders, special
symptoms or syndromes not elsewhere classiﬁed, diabetes melli-
tus, obesity and other hyperalimentation), having hospital inpa-
tient admissions (both psychiatric and nonpsychiatric related),
using antipsychotics, clozapine, and benzodiazepines, and having
higher medical service costs.
The propensity score matching process selected 2321 olanza-
pine patients who were the closest in propensity score values to
their counterparts in the quetiapine cohort. Results indicated that
after matching, none of the differences between the two cohorts
remained signiﬁcant, and the quetiapine and matched olanzapine
cohorts had similar demographics, baseline comorbidities, prior
medications, resource utilization, and costs (Table 2, column E).
Therefore, the two study groups were comparable at baseline.
The comparison of the two matched cohorts in the 12-month
postindex period is reported in Table 3. During the 1-year
follow-up period, the matched olanzapine patients had a lower
rate of psychiatric hospitalization (28.8% vs. 34.0%, P = 0.001)
and emergency visits (47.0% vs. 52.0%, P = 0.0007), and lower
pharmacy utilization across all drug categories analyzed (all
P < 0.05). They also used fewer antipsychotics on average com-
pared with quetiapine patients (1.64 vs. 1.81, P < 0.0001), had
fewer days with simultaneous antipsychotic use (47.8 vs.
66.9 days, P < 0.0001), and had on average 9.6 more days
without any antipsychotics compared with quetiapine patients
(114.1 vs. 104.5 days, P = 0.0009). Nevertheless, olanzapine
patients had a lower MPR of all antipsychotics (0.69 vs. 0.71,
P = 0.0003) compared with quetiapine patients.
In the 12-month postindex period, olanzapine patients had
statistically signiﬁcantly lower medical costs compared with que-
tiapine patients ($9897 vs. $11,218, P = 0.0128) and similar
drug costs ($6131 vs. $6014, P = 0.3257) (Table 4). The differ-
ences in medical costs were primarily driven by lower psychiatric
costs ($7352 vs. $9037, P = 0.0002), and, in particular, psychi-
atric hospitalization costs ($3149 vs. $4220, P = 0.0024). When
excluding the cost of the index drug, patients treated with olan-
zapine had lower psychotropic drug costs compared with
patients treated with quetiapine ($1828 vs. $2459, P < 0.0001).
In total, olanzapine patients had statistically signiﬁcantly lower
annual total costs compared with matched quetiapine patients
($16,028 vs. $17,232, P = 0.0279).
Results of the sensitivity analysis showed that these ﬁndings
are relatively insensitive to design speciﬁcations. Medical services
and total costs calculated in the responder analysis exhibited the
same trend as in the core analysis, but were generally no longer
statistically signiﬁcantly different. The difference-in-difference
analysis, controlling for any residual patients’ characteristics dif-
ferences using regression models, further conﬁrmed that olanza-
pine patients incurred lower costs than matched quetiapine
patients, and cost differences became even more statistically sig-
niﬁcant. After adjusting for baseline characteristics, the change in
medical service costs between the study period and baseline was
statistically signiﬁcantly lower for olanzapine patients (decreas-
ing by $2106) compared with quetiapine patients (which
decreased by $869). That is, controlling for differences in
baseline costs, treatment with olanzapine is associated with an
additional reduction in costs of $1237 (P = 0.0046, Table 5).
Similarly, during the 12-month study period, total costs increased
less for olanzapine ($1473) than for quetiapine patients ($2435),
yielding a net difference in total costs of $962 in favor of olan-
zapine compared with quetiapine (P = 0.032).
Discussion
This study used a retrospective cohort design to compare the
health-care resource utilization and treatment costs for schizo-
phrenia patients initiated on olanzapine versus those who were
initiated on quetiapine. To control for observed selection bias, a
propensity score matching method was used with an optimal
matching algorithm. The comparability of the quetiapine cohort
to the matched olanzapine cohort shows the impact of optimal
matching: although before matching, the quetiapine and full
olanzapine cohorts had substantially different baseline character-
istics, the matching process generated two balanced cohorts.
Nevertheless, unlike randomized clinical trials, using a propen-
sity score method in an observational study can only control for
observed covariates, and there maybe unobserved factors that
could affect both the choice of atypical drugs and the study
outcomes. Therefore, unobserved selection bias may still remain
in the study and confound the study ﬁndings.
This study found that based on two comparable cohorts at
baseline, schizophrenia patients covered by the Pennsylvania
Medicaid program treated with olanzapine had lower medical
and pharmaceutical resource utilization and were less costly than
patients treated with quetiapine in the 12 months following the
index drug prescription.
Speciﬁcally, in the 12-month study period, medical service
costs were $1321 lower for patients treated with olanzapine than
for those treated with quetiapine, of which $1071 were because
of lower psychiatric hospitalization costs. Total drug costs were
not signiﬁcantly different for patients in both treatment groups
(P = 0.33), but when excluding the index drugs, olanzapine
patients had $631 lower drug costs compared with patients
treated with quetiapine. Overall, the total health-care costs in the
12-month study period were $1204 lower for olanzapine patients
than for quetiapine patients. Therefore, olanzapine’s economic
advantage in other psychotropic drug costs and psychiatric hos-
pitalization costs more than offset the higher acquisition costs of
the drug, yielding lower total treatment costs compared with
quetiapine.
Higher rates for both psychiatric hospitalization and emer-
gency room visits were observed among patients in the quetiap-
ine group, as well as higher psychiatric hospitalization costs.
Both of these urgent care resource uses indicate that quetiapine
patients were probably more likely to experience relapses [17]. In
addition, quetiapine patients used more concomitant psychiatric
medications from each of the classes we examined, including
more antipsychotics compared with olanzapine patients. Never-
theless, quetiapine patients showed a slightly higher MPR com-
pared with olanzapine patients. A detailed treatment pattern
outcome comparison between olanzapine and quetiapine is
covered in a separate study [18].
The trend in the results observed was conﬁrmed by the sensi-
tivity analyses conducted and was consistent with some past
studies [30,31]. Some studies did not ﬁnd differences between
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quetiapine and olanzapine because of smaller sample size and
noncomparability of the study cohorts [19,20]. In addition, the
two studies analyzed patients who had at least 60 days of mono-
therapy, while the study group investigated in this study was
requested to have at least 30 days of monotherapy, which did not
force patients to be responders. Results of the sensitivity analysis
conducted among patients with 60 days of monotherapy indicate
that olanzapine patients had lower total costs than matched
quetiapine patients, although to a lesser extent than in the core
analysis. This implies that part of the total economic beneﬁt of
olanzapine is due to a better response proﬁle of olanzapine, which
is consistent with clinical ﬁndings in the CATIE study [4]. Never-
theless, an appropriate comparison of overall economic outcomes
would consider the cost advantage due to different response and
tolerability associated with the initial therapy of selection, as
shown in this study. Moreover, quetiapine patients have numeri-
cally more mental comorbidities during the follow-up period than
matched olanzapine patients (although not statistically signiﬁ-
cant). This indicates that patients treated with quetiapine are
responding less to treatment than patients treated with olanzap-
ine, which is also reﬂected by a higher utilization of psychotropic
drugs for quetiapine patients during the follow-up period.
Table 3 Comorbidities and outcomes for matched schizophrenia cohorts deﬁned over the 12-month postindex period
Olanzapine Quetiapine
P-valueN N
2321 2321
I. Comorbidities
Mean number of mental comorbidities (mean, SD) 1.45 1.69 1.51 1.66 0.1830
Charlson Comorbidity Index 0.61 1.38 0.60 1.31 0.6348
II. Medical resource utilization
Any psychiatric hospitalization 668 28.8% 789 34.0% 0.0001
Any nonpsychiatric hospitalization 552 23.8% 576 24.8% 0.4148
Any emergency visit 1091 47.0% 1206 52.0% 0.0007
III. Pharmacy utilization
Any use of clozapine 106 4.6% 164 7.1% 0.0003
Any use of antidepressants 1508 65.0% 1656 71.3% <0.0001
Any use of mood stabilizers 1205 51.9% 1343 57.9% <0.0001
Any use of benzodiazepines/hypnotics/anxiolytics 1104 47.6% 1210 52.1% 0.0020
Any use of antiparkinsonian medication 601 25.9% 670 28.9% 0.0214
Among users
MPR of all antipsychotics (mean, SD) 0.69 0.28 0.71 0.27 0.0003
Days of simultaneous use of antipsychotics (mean, SD) 47.8 94.0 66.9 107.8 <0.0001
Number of antipsychotic drugs used (mean, SD) 1.64 0.86 1.81 0.94 <0.0001
Antidepressants include tricyclics, MAOI, and second-generation antidepressants. McNemar’s tests are used to compare categorical variables; paired t-tests are used to compare continuous
variables, except for values calculated among users, which are compared using Wilcoxon tests.
MAOIs, monoamine oxidase inhibitors; MPR, medication possession ratio.
Table 4 Descriptive analysis of costs for matched schizophrenia cohorts over the 12-month postindex period
Costs
Olanzapine (N = 2321) Quetiapine (N = 2321) Difference
(olanzapine – quetiapine) P-valueMean SD Mean SD
Medical service costs $9,897 $18,377 $11,218 $18,592 ($1,321) 0.0128
Psychiatric costs $7,352 $14,282 $9,037 $16,904 ($1,685) 0.0002
Nonpsychiatric costs $2,546 $11,587 $2,181 $8,344 $365 0.2209
Psychiatric hospitalization costs $3,149 $10,638 $4,220 $13,838 ($1,071) 0.0024
Nonpsychiatric hospitalization costs $814 $7,024 $530 $2,617 $284 0.0668
Drug costs $6,131 $4,236 $6,014 $4,180 $117 0.3257
Psychotropic drug costs $4,788 $3,309 $4,609 $3,295 $179 0.0591
Psychotropic drug costs, excluding index drug $1,828 $2,131 $2,459 $2,477 ($631) <0.0001
Total costs $16,028 $19,182 $17,232 $19,162 ($1,204) 0.0279
P-values were generated by paired t-test.
Table 5 Regression-adjusted cost differences comparing matched schizophrenia cohorts
Olanzapine
(postindex – preindex)
Quetiapine
(postindex – preindex)
Difference
(olanzapine – quetiapine) P-value
Least squares mean cost differences
Medical service cost ($2106) ($869) ($1237) 0.0046
Psychiatric cost ($2017) ($587) ($1430) 0.0004
Psychiatric hospitalization cost ($1566) ($574) ($992) 0.0043
Drug cost $3578 $3304 $274 0.0059
Psychotropic drug cost $3097 $2736 $361 <0.0001
Psychotropic drug cost, excluding index drug $664 $965 ($301) <0.0001
Total costs $1473 $2435 ($962) 0.0320
Ordinary least squares regression was used to control for baseline characteristics.
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The results for olanzapine’s overall economic advantage are
consistent with ﬁndings from a cost-effectiveness study reported
for the CATIE trial [32]. The CATIE trial also used an intent-to-
treat analysis design and reported that the average monthly cost
savings associated with olanzapine compared with quetiapine
was $224 ($1433 vs. $1657), despite a higher antipsychotic
medication costs. Similar to ﬁndings reported in our study, the
majority of the CATIE-reported savings were because of the
reduced cost in inpatient services ($556 vs. $753 monthly costs).
The consistency of the results in our study with those of a
randomized clinical trial further validated the propensity score
optimal matching methodology employed in this study. The
study results are also consistent with those of a recent cost
analysis using California Medicaid database analyzing different
types of episodes, which found that olanzapine was associated
with lower total costs and psychiatric hospitalization costs than
quetiapine, although this study did not perform statistical tests
comparing the two drugs [33]. Nevertheless, Gianfrancesco et al.
(2006b) found to the contrary that olanzapine was associated
with a higher risk for hospitalization compared with quetiapine,
although the difference was not statistically signiﬁcant [34]. The
Gianfrancesco study allowed a treatment gap of up to 90 days,
which potentially included patients who used the drugs episodi-
cally. In addition, the study converted drug-speciﬁc dose to
risperidone-equivalent milligrams, which has been recognized as
“highly misleading” [34]. This is especially problematic when
that variable is controlled in the regression, because as shown in
the study, dose is a signiﬁcant predictor of hospitalization risk.
Finally, the study suffers from selection bias where the study
cohorts are not comparable, yet no sufﬁcient baseline informa-
tion were considered and matched. A regression analysis control-
ling for limited baseline variables was used. Nevertheless, in
contrast to propensity score matching, a conventional regression
model would superimpose assumptions about the model speciﬁ-
cation form with noninteractive effects, thereby potentially
biasing study ﬁndings when two cohorts are not comparable.
The economic comparison between olanzapine and quetiap-
ine is consistent with their relative clinical effectiveness. In addi-
tion to the CATIE trial that found olanzapine to have better
effectiveness as previously discussed, a meta-analysis summarized
clinical trials comparing atypical antipsychotics, and concluded
that olanzapine was signiﬁcantly more efﬁcacious than typical
antipsychotics, whereas quetiapine did not have a signiﬁcantly
better efﬁcacy [33].
Our study has several limitations. Costs estimates presented
here have the common limitations associated with claims data-
based studies, including the absence of detailed patient clinical
symptom and severity information and characteristics of pre-
scribing physicians. Although we attempted to control for selec-
tion bias by using propensity scores and adjusted for recorded
patient characteristics, prior resource utilization and cost infor-
mation, unobserved confounders (e.g., unobserved severity of
illness) may potentially affect results. Regarding generalizability,
relying on a single state’s Medicaid data may not be representa-
tive of the overall US Medicaid population. In addition, the
sample selection criterion of continuous eligibility during 2 years
may limit our study sample to a subgroup of Medicaid beneﬁ-
ciaries that may differ from other Medicaid beneﬁciaries. Further,
approximately 32% of schizophrenia patients are enrolled in the
Medicaid program, and results of this Medicaid data analysis
may not be generalizable to all schizophrenia patients [32]. The
data we used is from 1999 to 2003, which may also affect the
external validity of the study results, because prescribing practice
could change over time, which may inﬂuence the economic out-
comes. By using a propensity score matching method, we
excluded a large proportion of olanzapine patients. As a result,
the olanzapine cost advantages can only be applicable to olan-
zapine patients who are clinically similar to the olanzapine
matched cohort, and cannot be extended to the unmatched olan-
zapine patients who were excluded from the study. Nevertheless,
the outcomes comparison may not be applicable among these
excluded olanzapine patients because they were unlikely to
receive quetiapine in the real world because they had substan-
tially different baseline characteristics from those of the quetiap-
ine patients. Although this propensity score matching approach
allowed the two study cohorts to be comparable, unlike random-
ized clinical trials, this method does not balance unobserved
factors and confounders. Furthermore, we could not use covari-
ates (such as comorbid conditions) that were used to estimate the
likelihood of cohort assignment, and therefore, we could not
estimate the effect of those covariates on medical costs [35].
Moreover, because the cost analysis only covered 12 months, the
cost savings associated with olanzapine treatment might be more
or less important if observed over a longer period of time. Future
research is warranted to extend the comparison between olanza-
pine and quetiapine to a longer period of time. In addition,
this study could not estimate the causal effect of the two drug
therapies, but rather, it could only estimate the economic out-
comes associated with treatment initiation with olanzapine
versus quetiapine.
Finally, although both olanzapine and quetiapine were
approved for the treatment of bipolar conditions in recent years,
this study considered only schizophrenia patients; therefore, esti-
mating the resource utilization and costs of bipolar patients
requires further research using more recent data.
Conclusions
This study demonstrated that in the Pennsylvania Medicaid
schizophrenia population, after applying optimal matching algo-
rithm on propensity score, initiation of olanzapine was associ-
ated with lower medical resource utilization, in particular
psychiatric hospitalizations, and lower utilization of other con-
current psychotropic drugs. Although the acquisition costs of
olanzapine are higher than those for quetiapine, the beneﬁcial
impact of olanzapine on schizophrenia patients’ medical and
pharmaceutical resource utilization more than offsets the drug’s
acquisition costs. Therefore, schizophrenia patients treated with
olanzapine are less costly than those treated with quetiapine after
controlling for differences in patients’ characteristics. Most of the
economic beneﬁt was attributable to signiﬁcant reductions in
medical resource utilization and costs of psychiatric hospitaliza-
tions and other psychotropic drugs.
Source of ﬁnancial support: This study was presented at the 2007 Ameri-
can Psychiatric Association Annual Meeting, San Diego, CA, May 19–24,
2007, and was supported by funding from Eli Lilly and Company.
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